University of Pennsylvania Health System

U.S. Pelvic Fracture Patients Treated with New CurvaFix IM Implant

Thursday, October 14, 2021 - 2:01pm

The company will showcase the novel CurvaFix Implant in its booth (#422) and provide updates from recent U.S. cases using the CurvaFix Implant for fixation of pelvic and acetabular fractures.

Key Points: 
  • The company will showcase the novel CurvaFix Implant in its booth (#422) and provide updates from recent U.S. cases using the CurvaFix Implant for fixation of pelvic and acetabular fractures.
  • The new CurvaFix Implant has tremendous versatility allowing surgeons to follow the natural bone shape, filling the space, and achieving a stable construct.
  • The patients weve treated using the new implant have tolerated their surgeries well.
  • The companys first product is the CurvaFix IM Implant, which has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

Neuvotion Secures over $1M in Seed Funding to Commercialize Neurostimulation Technology

Thursday, October 14, 2021 - 1:15pm

DARIEN, Conn., Oct. 14, 2021 /PRNewswire/ -- Neuvotion, Inc ., an early-stage medical device company developing neurostimulation products for the rehabilitation and physical therapy markets, today announced that it has received over $1M in seed funding.

Key Points: 
  • DARIEN, Conn., Oct. 14, 2021 /PRNewswire/ -- Neuvotion, Inc ., an early-stage medical device company developing neurostimulation products for the rehabilitation and physical therapy markets, today announced that it has received over $1M in seed funding.
  • This seed funding will be used by Neuvotion to expand its team, conduct a multi-site clinical study, and seek FDA clearance for its initial product.
  • Further, Neuvotion secured exclusive worldwide rights to transformative technology developed by its founder, Chad Bouton, who is a professor at the Feinstein Institutes for Medical Research at Northwell Health.
  • We feel strongly that this technology can help transform lives for people with spinal cord injuries, strokes and other neurological conditions."

Pegsitacianine Demonstrates Tumor-Agnostic Real-Time Surgical Imaging in Phase 2 Study

Thursday, October 14, 2021 - 12:00pm

Pegsitacianine has previously been studied in a Phase 1 clinical trial where breast, head and neck, colorectal, and esophageal cancers were successfully imaged following an intravenous dose of pegsitacianine.

Key Points: 
  • Pegsitacianine has previously been studied in a Phase 1 clinical trial where breast, head and neck, colorectal, and esophageal cancers were successfully imaged following an intravenous dose of pegsitacianine.
  • The Phase 2 study results for pegsitacianine presented at the recent World Molecular Imaging Congress indicate this fluorescent nanoprobe has the potential to change the current surgical paradigm, said Dr. Newman.
  • The recently completed Phase 2 study (NCT03735680) was a non-randomized, open-label, multi-center study being conducted at three U.S. sites.
  • OncoNanos lead development candidate is pegsitacianine, a novel fluorescent nanoprobe, that is currently under study in Phase 2 clinical trials as a real-time surgical imaging agent for use in multiple cancer surgeries.

BioSig’s PURE EP System to be Featured in a Live Patient Case During Annual International Symposium on Ventricular Arrhythmias

Tuesday, October 12, 2021 - 2:15pm

VT 2021 has been developed to meet the educational needs of electrophysiologists, cardiologists, and other physicians and associated professionals interested in the pathophysiology and management of ventricular arrhythmias.

Key Points: 
  • VT 2021 has been developed to meet the educational needs of electrophysiologists, cardiologists, and other physicians and associated professionals interested in the pathophysiology and management of ventricular arrhythmias.
  • Treatments for ventricular arrhythmias have historically been complex due to the very challenging nature of these conditions.
  • To date, over 70 physicians have completed over 1500 patient cases with the PURE EP System across thirteen clinical sites.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Breastcancer.org Urges People to Get Informed About Clinical Trials

Tuesday, October 12, 2021 - 12:00pm

Several experts leading efforts to improve access to clinical trials will be speaking at the organization's virtual town hall on Wednesday, October 13, at 7 p.m.

Key Points: 
  • Several experts leading efforts to improve access to clinical trials will be speaking at the organization's virtual town hall on Wednesday, October 13, at 7 p.m.
  • Not being included in clinical trials may be one of the reasons that Black women have worse breast cancer outcomes than other racial and ethnic groups.
  • Read the full list and learn how people affected by breast cancer can find clinical trials on Breastcancer.org.
  • The Special Report was developed with medical experts and through interviews with Black women who participated in breast cancer clinical trials.

Reform Sought for Organ Donation Disparities, Inequities

Monday, October 4, 2021 - 4:05pm

However, COVID has reduced the number of organ donorsyou can't transplant from an infected patientso we're still facing delays and long waits."

Key Points: 
  • However, COVID has reduced the number of organ donorsyou can't transplant from an infected patientso we're still facing delays and long waits."
  • To operate at peak effectiveness, however, says Shain, the U.S. organ transplant system also needs to deal with its logistical issues.
  • Another approach , which Shain applies to his own company, is a network of alliances among organ transplant flight providers.
  • "Organ Procurement Organization (OPO) Conditions for Coverage Final Rule: Revisions to Outcome Measures for OPOS CMS-3380-F." CMS, cms.gov/newsroom/fact-sheets/organ-procurement-organization-opo-conditions-coverage-final-rule-revisions-outcome-measures-opos.

Spring Hills’ Post-Acute Care Facility Launches New Regional Partnerships to Advance Patient Care

Wednesday, September 15, 2021 - 2:44pm

Spring Hills , an innovative leader in post-acute care, senior living and home care with 35 locations across seven states, has established Spring Hills Post Acute Woodbury as a premier partner to regional health systems.

Key Points: 
  • Spring Hills , an innovative leader in post-acute care, senior living and home care with 35 locations across seven states, has established Spring Hills Post Acute Woodbury as a premier partner to regional health systems.
  • Spring Hills Post Acute Woodbury is one of five former Atrium facilities that officially joined the Spring Hills family in July 2021.
  • A bold innovator in the post-acute care sector, Spring Hills commenced management and oversight of the Atrium facility in January 2019.
  • Spring Hills Post Acute Woodbury serves as a model for success due to our teams collective, collaborative pursuit of extraordinary care.

Five-year Results Of The GORE® EXCLUDER® Iliac Branch Endoprosthesis Pivotal U.S. Multicenter Study Confirm Safety, Efficacy and Durability

Thursday, August 19, 2021 - 5:01pm

Results of the study confirmed the safety, efficacy and durability of the IBE for treatment of aortoiliac and iliac artery aneurysms.

Key Points: 
  • Results of the study confirmed the safety, efficacy and durability of the IBE for treatment of aortoiliac and iliac artery aneurysms.
  • Five-year primary patency of the internal iliac artery and external iliac artery IBE limbs was 95.1% and 100%, respectively.
  • Used in conjunction with the GORE EXCLUDER AAA Endoprosthesis, the IBE isolates the common iliac artery from systemic blood flow and preserves blood flow in the external iliac and internal iliac arteries.
  • For more information on the GORE EXCLUDER Iliac Branch Endoprosthesis and the GORE EXCLUDER Device family, visit goremedical.com .

Castle Biosciences Presents New Data Demonstrating DecisionDx®-SCC Complements Current Risk Assessment Methods in Patients with Cutaneous Squamous Cell Carcinoma of the Head and Neck

Friday, July 23, 2021 - 12:00pm

DecisionDx-SCC is Castles prognostic 40-gene expression profile (GEP) test for patients diagnosed with high-risk cutaneous squamous cell carcinoma (SCC), designed to use a patients tumor biology to predict individual risk of metastasis for patients with SCC and one or more risk factors.

Key Points: 
  • DecisionDx-SCC is Castles prognostic 40-gene expression profile (GEP) test for patients diagnosed with high-risk cutaneous squamous cell carcinoma (SCC), designed to use a patients tumor biology to predict individual risk of metastasis for patients with SCC and one or more risk factors.
  • The data further demonstrate that Castles DecisionDx-SCC test can provide clinicians with additional information on a patients metastatic risk to help them make more informed choices about their treatment and follow-up care.
  • All SCC tumor specimens were tested with DecisionDx-SCC and analyzed using Kaplan-Meier for metastasis-free survival (MFS) and Cox regression for risk of regional/distant metastasis.
  • DecisionDx-SCC is a 40-gene expression profile test that uses an individual patients tumor biology to predict individual risk of cutaneous squamous cell carcinoma metastasis for patients with one or more risk factors.

Manatt Bolsters Integrated Healthcare Capabilities With Addition of Noted Health System Leader

Monday, December 16, 2019 - 2:00pm

Manatt, Phelps & Phillips, LLP, a multidisciplinary, integrated professional services firm, announced today that Ralph Muller, former CEO of the University of Pennsylvania Health System (UPHS) will join as a national advisor in its Manatt Health group effective January 2, 2020.

Key Points: 
  • Manatt, Phelps & Phillips, LLP, a multidisciplinary, integrated professional services firm, announced today that Ralph Muller, former CEO of the University of Pennsylvania Health System (UPHS) will join as a national advisor in its Manatt Health group effective January 2, 2020.
  • Muller led the University of Chicago Hospitals and UPHS, two of the nations most renowned academic health systems.
  • Mullers leadership experience and depth of knowledge in healthcare management, policy and economics will enhance Manatt Healths advisory services to leading healthcare organizations across the country.
  • Manatt, Phelps & Phillips, LLP, is a leading professional services firm, providing integrated legal and consulting services to a global client base.